| Title: |
Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes |
| Authors: |
Karakas, M; Friede, T; Butler, J; Talha, KM; Placzek, M; Asendorf, T; Diek, M; Nosko, A; Stas, A; Kluge, S; Jarczak, D; DeHeer, G; Rybczynski, M; Bayes‐Genis, A; Böhm, M; Coats, AJS; Edelmann, F; Filippatos, G; Hasenfuß, G; Haverkamp, W; Lainscak, M; Landmesser, U; Macdougall, IC; Merkely, B; Pieske, BM; Pinto, FJ; Rassaf, T; Visser‐Rogers, JK; Rosano, G; Volterrani, M; von Haehling, S; Anker, MS; Doehner, W; Ince, H; Koehler, F; Savarese, G; Khan, MS; Kröhnert, UR; Gori, T; Trenkwalder, T; Akin, I; Paitazoglou, C; Kobielusz‐Gembala, I; Kuthi, L; Frey, N; Licka, M; Kääb, S; Laugwitz, K; Ponikowski, P; Anker, SD |
| Publisher Information: |
Wiley |
| Publication Year: |
2026 |
| Collection: |
St George's University of London: Repository |
| Description: |
Aims Intravenous iron has emerged as a guideline‐recommended therapy in patients with heart failure and iron deficiency, but the potential sex‐related differences in efficacy are unknown. We aimed to assess sex‐specific outcomes in the Intravenous Iron in Patients with Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality (FAIR‐HF2‐DZHK05) trial. Methods and results FAIR‐HF2 included 1105 heart failure patients with a left ventricular ejection fraction ≤45% and iron deficiency. A total of 368 women (mean age 68.7 ± 13.0 years) and 737 men (mean age 70.5 ± 11.0 years) were randomized to intravenous ferric carboxymaltose or placebo. The three primary endpoints were (i) time to cardiovascular death or first heart failure hospitalization, (ii) total heart failure hospitalizations, and (iii) time‐to‐first event of cardiovascular death or heart failure hospitalization only in patients with transferrin saturation |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf; application/vnd.openxmlformats-officedocument.wordprocessingml.document |
| Language: |
English |
| ISSN: |
1388-9842 |
| Relation: |
https://openaccess.sgul.ac.uk/id/eprint/117879/1/European%20J%20of%20Heart%20Fail%20-%202025%20-%20Karakas%20-%20Intravenous%20ferric%20carboxymaltose%20in%20heart%20failure%20with%20iron%20deficiency%20.pdf; https://openaccess.sgul.ac.uk/id/eprint/117879/2/ejhf3742-sup-0001-tables.docx; Karakas, M; Friede, T; Butler, J; Talha, KM; Placzek, M; Asendorf, T; Diek, M; Nosko, A; Stas, A; Kluge, S; et al. Karakas, M; Friede, T; Butler, J; Talha, KM; Placzek, M; Asendorf, T; Diek, M; Nosko, A; Stas, A; Kluge, S; Jarczak, D; DeHeer, G; Rybczynski, M; Bayes‐Genis, A; Böhm, M; Coats, AJS; Edelmann, F; Filippatos, G; Hasenfuß, G; Haverkamp, W; Lainscak, M; Landmesser, U; Macdougall, IC; Merkely, B; Pieske, BM; Pinto, FJ; Rassaf, T; Visser‐Rogers, JK; Rosano, G; Volterrani, M; von Haehling, S; Anker, MS; Doehner, W; Ince, H; Koehler, F; Savarese, G; Khan, MS; Kröhnert, UR; Gori, T; Trenkwalder, T; Akin, I; Paitazoglou, C; Kobielusz‐Gembala, I; Kuthi, L; Frey, N; Licka, M; Kääb, S; Laugwitz, K; Ponikowski, P; Anker, SD (2026) Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes. European Journal of Heart Failure, 27 (11). pp. 2328-2342. ISSN 1388-9842 https://doi.org/10.1002/ejhf.3742 SGUL Authors: Rosano, Giuseppe Massimo Claudio |
| DOI: |
10.1002/ejhf.3742 |
| Availability: |
https://openaccess.sgul.ac.uk/id/eprint/117879/; https://doi.org/10.1002/ejhf.3742 |
| Rights: |
cc_by_4 |
| Accession Number: |
edsbas.787D6E01 |
| Database: |
BASE |